HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

entacapone (Comtan)

structure given in first source

Also Known As:

Comtan; 2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; Comtess; Novartis brand of entacapone; OR 611; OR-611; Orion brand of entacapone; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide

Networked: 221 relevant articles (28 outcomes, 60 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Phenols: 309
  - Catechols: 85
    - entacapone: 221
- Nitriles: 34
  - entacapone: 221

Experts

1.	Müller, Thomas: 7 articles (06/2014 - 03/2006)
2.	Gordin, A: 7 articles (10/2004 - 05/2000)
3.	Leinonen, Mika: 5 articles (12/2015 - 05/2005)
4.	Poewe, Werner: 5 articles (12/2015 - 01/2004)
5.	Rascol, Olivier: 5 articles (07/2013 - 09/2004)
6.	Hauser, Robert A: 5 articles (07/2009 - 01/2004)
7.	Bremen, Dirk: 5 articles (05/2007 - 01/2004)
8.	Kaakkola, S: 5 articles (09/2006 - 06/2000)
9.	Brooks, D J: 5 articles (03/2005 - 04/2000)
10.	Kuoppamäki, Mikko: 4 articles (12/2015 - 06/2008)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 08/01/2003 - "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study." 10/01/2004 - "Significant improvement with entacapone treatment was detected in several quality-of-life measures, including the Parkinson Disease Questionnaire 39, the 36-item Short-Form Health Survey, the Parkinson's Symptom Inventory, and investigator and subject Clinical Global Assessments. " 07/01/2001 - "The study shows that entacapone is a cost-effective treatment in patients with Parkinson's disease: entacapone yields higher effectiveness in terms of both effectiveness measures (time without severe fluctuations and QALYs), while costs remain quite similar to those for usual care. " 03/01/2007 - "Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention." 08/01/2004 - "The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. "
2.	Dyskinesias (Dyskinesia) 08/01/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with most adverse effects being dyskinesias and gastrointestinal disorders. " 04/16/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with few reported adverse events, mainly dyskinesias and gastrointestinal disorders. " 05/01/2015 - "In advanced PD patients with motor fluctuations, IPX066 reduced off time and increased on time without troublesome dyskinesia compared to CD-LD immediate release and CD-LD with entacapone. " 01/01/2010 - "CLE is an attractive alternative for patients with nondisabling "wearing-off" or dyskinesia taking CL with or without entacapone. " 06/01/2007 - "Even though entacapone is indicated for advanced PD patients with motor fluctuation, the fluctuators commonly have dyskinesia and mental symptoms, which can become more troublesome with entacapone. "
3.	Schizophrenia (Dementia Praecox) 02/01/2014 - "To assess the efficacy of entacapone addition to antipsychotic treatment in patients with residual schizophrenia, we conducted a double-blind, randomised, placebo-controlled study for 12 wk of treatment with entacapone or placebo. " 02/01/2014 - "Therefore, this study does not support a therapeutic role for entacapone in residual schizophrenia. "
4.	Hypokinesia (Bradykinesia) 12/01/2011 - "Retrospective analysis, using the Bonferroni correction, of UPDRS motor subdomains further revealed that rasagiline, but not entacapone, significantly improved bradykinesia (P < 0.001) and showed trends for improvements in facial expression, speech, and axial impairment during OFF time. "
5.	Dyspnea (Shortness of Breath) 01/01/2009 - "His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone)."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Carbidopa (Lodosyn)
3.	Stalevo
4.	Catechol O-Methyltransferase (Methyltransferase, Catechol)
5.	tolcapone (Tasmar)
6.	Dopa Decarboxylase
7.	levodopa drug combination carbidopa (Nakom)
8.	rasagiline (Azilect)
9.	ropinirole (Requip)
10.	Complement System Proteins (Complement)

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Stents
3.	Denervation
4.	Aftercare (After-Treatment)